A Healthcare Investor’s Guide to “AI Exposure”

Walk the floor of any healthtech conference today and you’ll hear two stories told with equal conviction. The first is the hype narrative: AI will transform everything, from triage to treatment to drug discovery, and investors would be missing out on a once-in-a-lifetime opportunity to acquire such transformative technologies. The second is the cautionary one: most “AI software” assets are being priced as if they’ve already won—and many won’t. One seasoned operator put it simply: buying a vertical software product “powered by AI” can look clever right up until a foundation-model provider, hyperscaler, or incumbent workflow platform ships a comparable capability and turns your differentiator into a checkbox.

This is not a new pattern. In gold rushes, many of the most durable fortunes were made by the people selling the picks, shovels, rails, and refining equipment—not the mine owners. In the AI rush, the analogue is clear: the value often accrues to the platforms, infrastructure, and workflow control points that sit closest to distribution and switching costs (e.g. computer chips, cloud infrastructure, proprietary data sources, and the systems-of-record). Everyone else risks being trapped in a cycle of “feature parity” and margin compression.

As a healthcare investor, even if you’re not buying a pure-play AI platform business, an uncomfortable but practical question emerges: how urgently should you be adapting your portfolio companies—and how can they win? The impact of AI on a staffing business, contract manufacturer, medcomms agency, hospital, care home or “service orchestrator” like a teleradiology provider will vary significantly.

This article seeks to assess business model AI exposure for healthcare, life sciences and social care companies — sectors where AI’s impact is real, but often less about overnight disruption and more about where productivity gains, workflow control, and pricing power ultimately settle.

A necessary reality check: AI doesn’t remove accountability

Before frameworks and scorecards, one reminder: healthcare is not e-commerce. Even as models improve, supervision and governance will remain non-optional in many clinical use cases. “Human-in-the-loop” isn’t a transitional phase; in regulated settings it’s often the operating model. For investors underwriting healthcare assets today, the key question is not whether humans leave the loop, but how much productivity can be unlocked while keeping them in it.

We already see this in practice. Radiology algorithms may triage worklists or flag suspected findings, but liability, QA, and clinical acceptance still drive deployment constraints. In documentation, ambient scribes can draft, but clinicians remain accountable for content. In surgery, the futuristic picture isn’t “robots replace surgeons”; it’s experienced clinicians supervising more activity through better tooling, potentially across sites, while trained teams execute the physical components locally.

For healthcare investors, this matters because it shapes both diffusion speed and value at stake. The AI gains are real — but in healthcare, they usually arrive through gradual workflow redesign, governance, and change management, not instant structural change.

AI exposure can coincide with AI opportunity

A company can be highly exposed to AI without being rendered obsolete —and can have a large AI opportunity without being forced into urgent action tomorrow. What investors need is a way to separate:

Urgency to adapt: how quickly AI will change workflows, buyer expectations, and competitive dynamics in the sector; and

Ability to capture upside: whether the asset can capture upside and defend that position, rather than watching the benefits pass through to customers, intermediary platforms, or competitors.

The framework breaks this into five lenses (Exhibit A).

The five-lens checklist (and what it looks like in diligence)

1) Market diffusion speed

This is your “how quickly does the world move?” lens. In healthcare, diffusion speed depends less on model capability in a demo and more on the friction of scaled deployment. The buyer also matters – public systems such as the NHS typically lag in adoption, held back by weaker competitive and financial incentives, long procurement cycles and cultural resistance to change. This lens is likely to vary most across different business models. Core healthcare IT businesses, including EPR/PAS vendors and other pure-play software providers, face higher urgency to adapt because once AI is embedded into the product, adoption can become “default” — even if shifting buyer expectations remain constrained by customers’ tech readiness. In GxP-compliant CDMO processes, by contrast, validation, regulation and change control can slow scaled rollout irrespective of buyer demand.

2) Value at stake

Ask where the EBITDA is really coming from. AI bites hardest where value is tied to cognitive labour and repeatable information work—documentation, interpretation, coding, planning, coordination. But a second-order question matters more: can you monetise throughput gains, or will they be competed away? Diagnostic interpretation services (e.g. teleradiology/pathology) have a high value-at-stake profile because the core product is cognitive time. Clinical labs also have significant value at stake—less from “AI reads the test” and more from standardising operations, QC, routing, and turnaround time at scale.

3) Competitive vulnerability

This is where many investors underwrite the wrong risk. In many healthcare subsectors, the threat isn’t that AI “replaces” the service; it’s that AI modularises parts of it and shifts who controls the workflow. For example, staffing services are exposed not because clinicians disappear, but because AI can compress the coordination layer (matching, compliance, scheduling), pushing the market toward platform-like economics and pressuring agency take rates.

4) Enduring advantage

In traditional healthcare, defensibility is often non-software: referral capture and distribution; physical footprint and capacity; regulatory/accreditation and quality systems; deep integrations and switching costs; trusted brand and outcomes track record. In that regard, CDMOs can be highly defensible: even if AI improves process development and batch release, scale, quality systems, and track record remain scarce. For hospitals, local catchment, capex intensity, and regulation dampen disruption and preserve structural moats—AI is more “efficiency race” than market reconfiguration in the near term.

5) Early adopter value capture

This is the crux for investors: AI creates surplus, but surplus doesn’t automatically accrue to the operator doing the work. It often gets competed away or passed through—unless the business can redesign pricing and the offer. Medcomms agencies face rapid drafting commoditisation; the defensible edge shifts to compliance-grade workflows, specialist expertise, and strategy. By contrast, novel device manufacturers can use AI to create a “device + software + data” bundle that defends pricing or even augments it—if they can execute on evidence generation, integration, and regulatory posture.

AI sector impact

AI impact is uneven and often counterintuitive acrossHealthcare Services and Life Sciences & MedTech. The sector heatmaps in Exhibits B and C are deliberately directional: they are not forecasts of AI adoption, but a way to compare where AI is most likely to change workflows, pricing expectations, and value capture over a visible investment horizon today. Some standout examples include:

Hospitals and social care: lowest urgency; the biggest near-term gains are in documentation, coordination, and admin—market structure and operating model impact is expected to be limited

Core healthcare IT: very high exposure and urgency. AI becomes a platform requirement; value risks migrating to an AI workflow layer if incumbents don’t ship fast

Bioinformatics platforms: similarly high urgency to adapt, but ability to win depends heavily on workflow integration and access to rights-secured proprietary data; narrow point tools are likely to commoditise quickly

Clinical labs and diagnostic support services: moderate operational exposure with strong productivity upside, but value capture is constrained by buyer pressure unless contracts shift towards TAT, quality, reliability or availability guarantees and first movers can capitalise on those

CDMOs: meaningful upside via right-first-time and faster release, but diffusion is slower and disruption is limited—AI is an operational edge more than an operating model shift

Hospitals and social care: lowest urgency; the biggest near-term gains are in documentation, coordination, and admin—market structure and operating model impact is expected to be limited

An investor playbook: how to diligence “AI exposure” without getting lost in demos

Map the value chain into tasks, not functions. Identify where cognitive labour, coordination, and documentation sit—and what’s truly physical/relational

Stress-test value capture. Ask: If productivity improves 20%, who keeps the 20%? Look at pricing units, contract terms, buyer concentration, and pass-through risk

Run an “execution readiness” gate. Data rights, governance, integration capacity, cyber capability, and change management determine whether upside is realisable

Translate into a 100-day plan. Pick 2–3 high-ROI use cases (often admin/workflow first), build governance, and decide build/buy/partner with discipline

The Bottom Line

Healthcare investors don’t need another list of AI use cases. They need a way to avoid two mistakes: overpaying for “AI inside” software assets with fragile moats, and underinvesting in AI capability where the sector is about to reset expectations.

The most durable value is likely to accrue to businesses that (1) own the workflow control points, (2) control scarce assets that stay scarce in an AI world, and (3) can redesign their commercial model to capture surplus rather than passing it through.

The AI rush is real. But the winners will look less like “AI stickers on products” and more like disciplined operators and platforms that understand where the surplus goes—and manage to get there first.